Sotatercept (Merck & Co., Inc.) is an investigational therapy with a new mechanism of action that is administered subcutaneously every 3 weeks. A decision on its regulatory approval is anticipated by March 26, 2024. The Institute for Clinical and Economic Review (ICER) evaluated sotatercept for PAH. This report presents the summary of our systematic literature review and cost-effectiveness analysis and highlights the key policy recommendations discussed at the public meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) on December 1, 2023. The ICER Final Evidence Report on sotatercept for PAH is available at https://icer.org/wp-content/uploads/2023/05/PAH_Final-Evidence-Report_For-Publication_01082024.pdf
